Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review

Overview

Journal JAMA Psychiatry

Publisher American Medical Association

Specialty Psychiatry

Date 2020 Apr 9

PMID 32267484

Citations 97

Authors

Martin P Paulus

Jennifer L Stewart

Affiliations

Soon will be listed here.

Abstract

Importance: The prevalence of and mortality associated with methamphetamine use has doubled during the past 10 years. There is evidence suggesting that methamphetamine use disorder could be the next substance use crisis in the United States and possibly worldwide.

Observation: The neurobiology of methamphetamine use disorder extends beyond the acute effect of the drug as a monoaminergic modulator and includes intracellular pathways focused on oxidative stress, neurotoxic and excitotoxic effects, and neuroinflammation. Similarly, the clinical picture extends beyond the acute psychostimulatory symptoms to include complex cardiovascular and cerebrovascular signs and symptoms that need to be identified by the clinician. Although there are no pharmacologic treatments for methamphetamine use disorder, cognitive behavioral therapy, behavioral activation, and contingency management show modest effectiveness.

Conclusions And Relevance: There is a need to better understand the complex neurobiology of methamphetamine use disorder and to develop interventions aimed at novel biological targets. Parsing the disorder into different processes (eg, craving or mood-associated alterations) and targeting the neural systems and biological pathways underlying these processes may lead to greater success in identifying disease-modifying interventions. Finally, mental health professionals need to be trained in recognizing early cardiovascular and cerebrovascular warning signs to mitigate the mortality associated with methamphetamine use disorder.

Citing Articles

A multicenter cross-sectional study of gambling disorder among patients with methamphetamine use disorder in drug rehabilitation centers: prevalence, correlates, and network analysis.

Peng P, Hao Y, Zhang X, Ma Y, Liu X, Shen D Ann Gen Psychiatry. 2025; 24(1):12.

PMID: 40033412 PMC: 11877697. DOI: 10.1186/s12991-025-00546-0.

An electroencephalography connectome predictive model of craving for methamphetamine.

Zhang H, Yu Q, Zhang X, Zhang Y, Huang T, Ding J Int J Clin Health Psychol. 2025; 25(1):100551.

PMID: 40007948 PMC: 11850752. DOI: 10.1016/j.ijchp.2025.100551.

Decreasing β-Catenin Leads to Altered Endothelial Morphology, Increased Barrier Permeability and Cognitive Impairment During Chronic Methamphetamine Exposure.

Qiu H, Zhang M, Chen C, Wang H, Yue X Int J Mol Sci. 2025; 26(4).

PMID: 40003980 PMC: 11854931. DOI: 10.3390/ijms26041514.

Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.

Khan R, Turner A, Berk M, Walder K, Rossell S, Guerin A Biomolecules. 2025; 15(2).

PMID: 40001609 PMC: 11852989. DOI: 10.3390/biom15020306.

Impaired olfactory bulb neurogenesis mediated by Notch1 contributes to olfactory dysfunction in mice chronically exposed to methamphetamine.

Gu C, Wang Z, Luo W, Ling H, Cui X, Deng T Cell Biol Toxicol. 2025; 41(1):46.

PMID: 39976779 PMC: 11842540. DOI: 10.1007/s10565-025-10004-y.

References

Hser Y, Evans E, Huang D, Brecht M, Li L . Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav. 2008; 33(12):1581-9. PMC: 2819270. DOI: 10.1016/j.addbeh.2008.07.024. View

Paratz E, Zhao J, Sherwen A, Scarlato R, MacIsaac A . Is an Abnormal ECG Just the Tip of the ICE-berg? Examining the Utility of Electrocardiography in Detecting Methamphetamine-Induced Cardiac Pathology. Heart Lung Circ. 2017; 26(7):684-689. DOI: 10.1016/j.hlc.2016.11.005. View

Rawson R, Chudzynski J, Gonzales R, Mooney L, Dickerson D, Ang A . The Impact of Exercise On Depression and Anxiety Symptoms Among Abstinent Methamphetamine-Dependent Individuals in A Residential Treatment Setting. J Subst Abuse Treat. 2015; 57:36-40. PMC: 4560957. DOI: 10.1016/j.jsat.2015.04.007. View

Moszczynska A, Callan S . Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment. J Pharmacol Exp Ther. 2017; 362(3):474-488. PMC: 11047030. DOI: 10.1124/jpet.116.238501. View

Kandel D, Kandel E . The Gateway Hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatr. 2014; 104(2):130-7. DOI: 10.1111/apa.12851. View

Lappin J, Roxburgh A, Kaye S, Chalmers J, Sara G, Dobbins T . Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population. Int J Drug Policy. 2016; 38:16-20. DOI: 10.1016/j.drugpo.2016.10.018. View

Otten R, Mun C, Dishion T . The social exigencies of the gateway progression to the use of illicit drugs from adolescence into adulthood. Addict Behav. 2017; 73:144-150. PMC: 6946384. DOI: 10.1016/j.addbeh.2017.05.011. View

Kohno M, Link J, Dennis L, McCready H, Huckans M, Hoffman W . Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies. Pharmacol Biochem Behav. 2019; 179:34-42. PMC: 6637953. DOI: 10.1016/j.pbb.2019.01.007. View

Moallem N, Courtney K, Ray L . The relationship between impulsivity and methamphetamine use severity in a community sample. Drug Alcohol Depend. 2018; 187:1-7. PMC: 6410745. DOI: 10.1016/j.drugalcdep.2018.01.034. View

10.

Hartel-Petri R, Krampe-Scheidler A, Braunwarth W, Havemann-Reinecke U, Jeschke P, Looser W . Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings. Pharmacopsychiatry. 2017; 50(3):96-104. DOI: 10.1055/s-0043-105500. View

11.

Lyoo I, Yoon S, Kim T, Lim S, Choi Y, Kim J . Predisposition to and effects of methamphetamine use on the adolescent brain. Mol Psychiatry. 2015; 20(12):1516-24. PMC: 5653271. DOI: 10.1038/mp.2014.191. View

12.

Barr A, Panenka W, MacEwan G, Thornton A, Lang D, Honer W . The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006; 31(5):301-13. PMC: 1557685. View

13.

Wang L, Chen C, Lin S, Chen Y, Xu K, Huang M . Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls. Psychopharmacology (Berl). 2018; 235(7):2113-2121. DOI: 10.1007/s00213-018-4910-z. View

14.

McKetin R, Dawe S, Burns R, Hides L, Kavanagh D, Teesson M . The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug Alcohol Depend. 2016; 161:104-9. DOI: 10.1016/j.drugalcdep.2016.01.018. View

15.

Schurer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R . Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. JACC Heart Fail. 2017; 5(6):435-445. DOI: 10.1016/j.jchf.2017.02.017. View

16.

Lecomte T, Dumais A, Dugre J, Potvin S . The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Res. 2018; 268:189-192. DOI: 10.1016/j.psychres.2018.05.033. View

17.

Young K, Siegle G, Zotev V, Phillips R, Misaki M, Yuan H . Randomized Clinical Trial of Real-Time fMRI Amygdala Neurofeedback for Major Depressive Disorder: Effects on Symptoms and Autobiographical Memory Recall. Am J Psychiatry. 2017; 174(8):748-755. PMC: 5538952. DOI: 10.1176/appi.ajp.2017.16060637. View

18.

Glasner-Edwards S, Mooney L, Ang A, Garneau H, Hartwell E, Brecht M . Mindfulness Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. Mindfulness (N Y). 2017; 8(1):126-135. PMC: 5300086. DOI: 10.1007/s12671-016-0586-9. View

19.

Gowin J, Harle K, Stewart J, Wittmann M, Tapert S, Paulus M . Attenuated insular processing during risk predicts relapse in early abstinent methamphetamine-dependent individuals. Neuropsychopharmacology. 2013; 39(6):1379-87. PMC: 3988541. DOI: 10.1038/npp.2013.333. View

20.

Borgmann K, Ghorpade A . Methamphetamine Augments Concurrent Astrocyte Mitochondrial Stress, Oxidative Burden, and Antioxidant Capacity: Tipping the Balance in HIV-Associated Neurodegeneration. Neurotox Res. 2017; 33(2):433-447. PMC: 6003420. DOI: 10.1007/s12640-017-9812-z. View